Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ibuprofen + phenylephrine hydrochloride is a fixed-dose combination pharmaceutical product used for the temporary relief of symptoms associated with the common cold, flu, and upper respiratory tract infections. It combines **ibuprofen**, a non-steroidal anti-inflammatory drug (NSAID) of the propionic acid derivative class, with **phenylephrine hydrochloride**, a sympathomimetic decongestant. Ibuprofen provides analgesic, antipyretic, and anti-inflammatory effects by non-selectively inhibiting the cyclooxygenase enzymes COX-1 and COX-2, thereby reducing the synthesis of pro-inflammatory prostaglandins. Phenylephrine hydrochloride acts as a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction of the arterioles in the nasal mucosa, which leads to a reduction in swelling and congestion of the nasal passages. This combination is typically formulated as an immediate-release oral tablet and is widely available over-the-counter (OTC) in many regions, with various generic versions undergoing bioequivalence studies to match reference products like Advil Congestion Relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + phenylephrine hydrochloride.